Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Dispersibility and Storage Stability Optimization of High Dose Isoniazid Dry Powder Inhalation Formulations with L-Leucine or Trileucine.

Sibum I, Hagedoorn P, Kluitman MPG, Kloezen M, Frijlink HW, Grasmeijer F.

Pharmaceutics. 2019 Dec 25;12(1). pii: E24. doi: 10.3390/pharmaceutics12010024.

2.

A comparative analysis of changes in pMDI drug dose delivery before and after detergent coating using five antistatic valved holding chambers.

Hagedoorn P, Bawary W, Frijlink HW, Grasmeijer F.

J Allergy Clin Immunol Pract. 2019 Oct 5. pii: S2213-2198(19)30847-5. doi: 10.1016/j.jaip.2019.09.021. [Epub ahead of print] No abstract available.

3.

Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease.

Luinstra M, Rutgers W, van Laar T, Grasmeijer F, Begeman A, Isufi V, Steenhuis L, Hagedoorn P, de Boer A, Frijlink HW.

Ther Adv Chronic Dis. 2019 Jun 21;10:2040622319857617. doi: 10.1177/2040622319857617. eCollection 2019.

4.

Characterization and Formulation of Isoniazid for High-Dose Dry Powder Inhalation.

Sibum I, Hagedoorn P, Frijlink HW, Grasmeijer F.

Pharmaceutics. 2019 May 13;11(5). pii: E233. doi: 10.3390/pharmaceutics11050233.

5.

Challenges for pulmonary delivery of high powder doses.

Sibum I, Hagedoorn P, de Boer AH, Frijlink HW, Grasmeijer F.

Int J Pharm. 2018 Sep 5;548(1):325-336. doi: 10.1016/j.ijpharm.2018.07.008. Epub 2018 Jul 2. Review.

6.

Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis.

Akkerman OW, Grasmeijer F, de Lange WCM, Kerstjens HAM, de Vries G, Bolhuis MS, Alffenaar JW, Frijlink HW, Smith G, Gajraj R, de Zwaan R, Hagedoorn P, Dedicoat M, van Soolingen D, van der Werf TS.

Eur Respir J. 2018 Mar 22;51(3). pii: 1702490. doi: 10.1183/13993003.02490-2017. Print 2018 Mar. No abstract available.

7.

A levodopa dry powder inhaler for the treatment of Parkinson's disease patients in off periods.

Luinstra M, Grasmeijer F, Hagedoorn P, Moes JR, Frijlink HW, de Boer AH.

Eur J Pharm Biopharm. 2015 Nov;97(Pt A):22-9. doi: 10.1016/j.ejpb.2015.10.003. Epub 2015 Oct 13.

8.

Recent advances in the fundamental understanding of adhesive mixtures for inhalation.

Grasmeijer F, Grasmeijer N, Hagedoorn P, Frijlink HW, Haaije de Boer A.

Curr Pharm Des. 2015;21(40):5900-14. Review.

PMID:
26446471
9.

A proposed definition of the 'activity' of surface sites on lactose carriers for dry powder inhalation.

Grasmeijer F, Frijlink HW, de Boer AH.

Eur J Pharm Sci. 2014 Jun 2;56:102-4. doi: 10.1016/j.ejps.2014.02.012. Epub 2014 Mar 5.

PMID:
24613490
10.

The dispersion behaviour of dry powder inhalation formulations cannot be assessed at a single inhalation flow rate.

Grasmeijer F, de Boer AH.

Int J Pharm. 2014 Apr 25;465(1-2):165-8. doi: 10.1016/j.ijpharm.2014.02.024. Epub 2014 Feb 15.

PMID:
24548720
11.

New mechanisms to explain the effects of added lactose fines on the dispersion performance of adhesive mixtures for inhalation.

Grasmeijer F, Lexmond AJ, van den Noort M, Hagedoorn P, Hickey AJ, Frijlink HW, de Boer AH.

PLoS One. 2014 Jan 28;9(1):e87825. doi: 10.1371/journal.pone.0087825. eCollection 2014.

12.

Drug content effects on the dispersion performance of adhesive mixtures for inhalation.

Grasmeijer F, Hagedoorn P, Frijlink HW, de Boer AH.

PLoS One. 2013 Aug 14;8(8):e71339. doi: 10.1371/journal.pone.0071339. eCollection 2013.

13.

Mixing time effects on the dispersion performance of adhesive mixtures for inhalation.

Grasmeijer F, Hagedoorn P, Frijlink HW, de Boer HA.

PLoS One. 2013 Jul 2;8(7):e69263. doi: 10.1371/journal.pone.0069263. Print 2013.

14.

Characterisation of high dose aerosols from dry powder inhalers.

Grasmeijer F, Hagedoorn P, Frijlink HW, de Boer AH.

Int J Pharm. 2012 Nov 1;437(1-2):242-9. doi: 10.1016/j.ijpharm.2012.08.020. Epub 2012 Aug 19.

PMID:
22939966
15.

Aerosol drug delivery: developments in device design and clinical use.

Rottier B, Grasmeijer F, Hagedoorn P, de Boer AH.

Lancet. 2011 Sep 10;378(9795):981-2; author reply 982. doi: 10.1016/S0140-6736(11)61444-X. No abstract available.

PMID:
21907858

Supplemental Content

Loading ...
Support Center